Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quemliclustat + nab-paclitaxel + gemcitabine
- Development stage
- Phase 3
- Lead developer
- Arcus Biosciences
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a **combination therapy** involving quemliclustat (a small molecule CD73 inhibitor), nab-paclitaxel (an albumin-bound formulation of paclitaxel), and gemcitabine (a nucleoside analog chemotherapeutic). Quemliclustat inhibits CD73, reducing adenosine production in the tumor microenvironment—a pathway exploited by tumors to evade immune response, particularly relevant in KRAS-mutated cancers such as pancreatic ductal adenocarcinoma. Nab-paclitaxel disrupts microtubule function as a cytotoxic agent, and gemcitabine inhibits DNA synthesis as an antimetabolite. This regimen is under **phase 3 clinical investigation** as a first-line treatment for metastatic pancreatic cancer[1][3][7].
- Other names
- quemliclustat plus nab-paclitaxel plus gemcitabinequemliclustat + Gem-NP
02
Targets
NT5E (Cluster of Differentiation 73)DNA polymerase familyTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on quemliclustat + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quemliclustat + nab-paclitaxel + gemcitabine.